aTyr Pharma (ATYR) PT Lowered to $1 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts ATYR Hot Sheet
Price: $6.29 --0%
Rating Summary:
3 Buy, 7 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 15 | New: 11
Rating Summary:
3 Buy, 7 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 15 | New: 11
Join SI Premium – FREE
RBC Capital analyst Brian Abrahams lowered the price target on aTyr Pharma (NASDAQ: ATYR) to $1.00 (from $1.50) while maintaining a Sector Perform rating.
You May Also Be Interested In
- Hinge Health Inc (HNGE) PT Raised to $134 at Canaccord
- PT Telekomunikasi Indonesia Tbk (TLKM:IJ) (TLKMF) PT Lowered to IDR2,180 at JPMorgan
- Varun Beverages Ltd (VBL:IN) PT Lowered to INR490 at JPMorgan
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
